drugset / Trial / NCT04691154
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
NaSingle-groupOpen-labelTreatment
Summary
This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2025-03-20
- Completion
- 2031-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil | Other / unclassified | — | Inhaled |